Tysabri could be a €3bn drug says Elan

UPDATE: Pharma company Elan saw its share price shoot up after its chairman said that its multiple sclerosis treatment Tysabri may become a $3 billion drug.

24th May, 2012
Elan: share price rises

Dublin-based pharma company Elan saw its share price shoot up after its chairman said that its multiple sclerosis treatment Tysabri may become a $3 billion drug.

At 1500 the shares were trading up 2.8 per cent while the broader market was up one per cent.

Speaking at the company’s AGM, Robert Ingram also said that he expects probable clarity this year on the company’s Alzheimer’s compound Bapineuzumab. Elan collaborates on that drug with Pfizer in a 50:50 joint...

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader

Trial

€1

Unlimited Access for 1 Month

Get basic

*New subscribers only

You can cancel any time.

Annual

€200

€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.

Quarterly

€55

€42

90 Day Pass

You can cancel any time.

2 Yearly

€315

€248

Unlimited Access for 2 Years

You can cancel any time.

Team Pass

Get a Business Account for you and your team

Share this post

Related Stories

The year in review

Legacy Richie Oakley 1 year ago

Newsround: What Thursday’s papers say

Legacy Leanna Byrne 5 years ago

More cycle routes, expansion of Luas to Bray and new bus network proposed

Legacy Digital Desk 5 years ago